A parallel study showed administrations of ASOs targeting DGAT2 in HFD-fed mice and ob/ob mice both efficiently reduced liver Dgat2, resulting in lowered intrahepatic TG level and attenuated hyperlipidemia, as well as reduction of hepatic steatosis.309. This evidence concerns the gene DGAT2 and fatty liver disease.